Laurus Labs, Krka to establish JV company in Hyderabad

Hyderabad: Krka, an international generic pharmaceutical company in Novo Mesto, Slovenia and Laurus Labs have reached an agreement to establish a joint venture company Krka Pharma Pvt. Ltd. in Hyderabad, India.

Krka will hold 51% and Laurus 49% share in the joint venture. The registered capital of the newly founded company amounts up to Indian rupees equivalent to 50 million euros. The joint venture will enable the production of finished products for the new markets, including the Indian market.

Krka and Laurus have been working together contractually for many years and their businesses complement each other. The partners have discussed opportunities to strengthen co-operation and create synergies by combining their knowledge and resources.

Krka and Laurus have agreed to establish a joint venture company Krka Pharma Pvt. Ltd. with registered seat in Hyderabad, India. Krka will hold 51% and Laurus 49% share in the joint venture company. It is expected that the necessary procedures and documentation for the registration of the new joint venture company will be finalised by the end of March 2024. The parties have agreed on a step-by-step development of the joint venture company. The newly formed company will develop a plan to enter the Indian market and other markets outside the European Union where neither party is currently present with its finished products.